Provided by Tiger Trade Technology Pte. Ltd.

MetLife

95.17
-1.3400-1.39%
Post-market: 95.750.5800+0.61%19:48 EDT
Volume:2.90M
Turnover:276.78M
Market Cap:60.70B
PE:18.25
High:96.57
Open:96.37
Low:95.13
Close:96.51
52wk High:100.93
52wk Low:67.33
Shares:637.80M
Float Shares:528.18M
Volume Ratio:1.14
T/O Rate:0.55%
Dividend:2.30
Dividend Rate:2.41%
EPS(TTM):5.22
EPS(LYR):4.71
ROE:13.09%
ROA:0.45%
PB:2.21
PE(LYR):20.21

Loading ...

UBS Sticks to Its Buy Rating for Metlife (MET)

TIPRANKS
·
Jul 08

UBS Adjusts Price Target on MetLife to $105 From $102

MT Newswires Live
·
Jul 08

MetLife Keeps Quarterly Dividend at $0.5925 a Share, Payable Sept. 8 to Shareholders of Record on Aug. 4

MT Newswires Live
·
Jul 08

Metlife - Declares Q3 2026 Common Stock Dividend of $0.59 Per Share

THOMSON REUTERS
·
Jul 08

Press Release: Metlife Declares Third Quarter 2026 Common Stock Dividend

Dow Jones
·
Jul 08

MetLife Study Reveals Tax Planning Gaps in High-Value Home Sales

Deep News
·
Jul 08

Metlife is Maintained at Overweight by Barclays

Dow Jones
·
Jul 08

Metlife Poll Shows High-value Home Sellers Seek Tax-planning Guidance as Capital Gains Rise

Reuters
·
Jul 07

Everest and Metlife Expand Bereavement and Legacy Support to Ireland

THOMSON REUTERS
·
Jul 07

Lincoln National Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 07

Principal Financial, Reinsurance Group of America, MetLife Seen Backed by Q2 Trends, Morgan Stanley Says

MT Newswires Live
·
Jul 07

Metlife is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jul 06

Barclays Adjusts MetLife Price Target to $94 From $93

MT Newswires Live
·
Jul 06

MetLife price target raised to $103 from $93 at Morgan Stanley

TIPRANKS
·
Jul 06

MetLife (MET) Launches NQA FA, Is The Stock Already Close To Fair Value?

Simply Wall St.
·
Jul 03

Lincoln National Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 03

Movement Alert|MetLife Rises 3.12% in Regular Trading, Q2 Investment Income Guidance Confirms Solid Progress Toward Full-Year Target

Market Focus
·
Jul 03

HUTCHMED's Savolitinib Gains Conditional NMPA Approval for MET-Amplified Gastric Cancer

Stock News
·
Jul 02

HUTCHMED Wins China Nod for ORPATHYS in MET-Amplified Gastric Cancer

TIPRANKS
·
Jul 02

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

GlobeNewswire
·
Jul 02